A Novel Desensitization Protocol for Infliximab Hypersensitivity in a 13-Year Old Patient with Pustular Psoriasis
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Drug hypersensitivity reactions to infliximab have been reported in pediatric patients. At times, these patients may need infliximab administration in spite of hypersensitivity. However, only a few reports of desensitization protocols are available in the literature in pediatric patients.
CASE REPORT: We report a case of immediate hypersensitivity reaction to intravenous infliximab in a 13-year-old child suffering from pustular psoriasis who eventually underwent a 14 step desensitization protocol for the administration of infliximab in a pediatric intensive care unit.
RESULTS AND CONCLUSION: Although our desensitization protocol was safe and effective, we recommend the entire desensitization procedure to be performed under the supervision of experienced personnel in a pediatric intensive care unit. Future studies with larger sample size are needed to confirm our findings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Current drug safety - 14(2019), 2 vom: 18., Seite 158-162 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Behera, Sapan Kumar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
B72HH48FLU |
|---|
| Anmerkungen: |
Date Completed 06.01.2020 Date Revised 06.01.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1574886314666190119115632 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM292872828 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM292872828 | ||
| 003 | DE-627 | ||
| 005 | 20231225074058.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1574886314666190119115632 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0976.xml |
| 035 | |a (DE-627)NLM292872828 | ||
| 035 | |a (NLM)30659548 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Behera, Sapan Kumar |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Novel Desensitization Protocol for Infliximab Hypersensitivity in a 13-Year Old Patient with Pustular Psoriasis |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.01.2020 | ||
| 500 | |a Date Revised 06.01.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Drug hypersensitivity reactions to infliximab have been reported in pediatric patients. At times, these patients may need infliximab administration in spite of hypersensitivity. However, only a few reports of desensitization protocols are available in the literature in pediatric patients | ||
| 520 | |a CASE REPORT: We report a case of immediate hypersensitivity reaction to intravenous infliximab in a 13-year-old child suffering from pustular psoriasis who eventually underwent a 14 step desensitization protocol for the administration of infliximab in a pediatric intensive care unit | ||
| 520 | |a RESULTS AND CONCLUSION: Although our desensitization protocol was safe and effective, we recommend the entire desensitization procedure to be performed under the supervision of experienced personnel in a pediatric intensive care unit. Future studies with larger sample size are needed to confirm our findings | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a BAT | |
| 650 | 4 | |a Desensitization | |
| 650 | 4 | |a infliximab | |
| 650 | 4 | |a monoclonal antibody | |
| 650 | 4 | |a pediatric | |
| 650 | 4 | |a psoriasis. | |
| 650 | 7 | |a Infliximab |2 NLM | |
| 650 | 7 | |a B72HH48FLU |2 NLM | |
| 700 | 1 | |a Selvarajan, Sandhiya |e verfasserin |4 aut | |
| 700 | 1 | |a Mathews, Jerene |e verfasserin |4 aut | |
| 700 | 1 | |a Shajil, Chandana |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Saibal |e verfasserin |4 aut | |
| 700 | 1 | |a Munisamy, Malathi |e verfasserin |4 aut | |
| 700 | 1 | |a Xavier, Alphienes Stanley |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug safety |d 2006 |g 14(2019), 2 vom: 18., Seite 158-162 |w (DE-627)NLM181475790 |x 2212-3911 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2019 |g number:2 |g day:18 |g pages:158-162 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1574886314666190119115632 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2019 |e 2 |b 18 |h 158-162 | ||